0
0 (0%)
Cogent Biosciences, Inc. [UMRX]
Source:
Company Overview
Cogent Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Our approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | 617-945-5576 |
| Industry | manufacturing |
| CEO | Andrew Robbins |
| Website | www.cogentbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-275.9 |
| Net Income | $-255.9 |
| Net Cash | $44.9 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -79.8% |
| Profit as % of Stockholder Equity | -99.8% |
Management Effectiveness
| Return on Equity | -99.8% |
| Return on Assets | -78% |
| Turnover Ratio | |
| EBITA | $-275.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $327.9 |
| Total Liabilities | $71.6 |
| Operating Cash Flow | $-207.8 |
| Investing Cash Flow | $38.3 |
| Financing Cash Flow | $214.5 |
